69
Participants
Start Date
February 11, 2022
Primary Completion Date
October 24, 2024
Study Completion Date
October 24, 2024
E-602
Subjects will receive E-602 (administered weekly, via IV infusion).
Cemiplimab
Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).
Columbia University, New York
Roswell Park Comprehensive Cancer Center, Buffalo
University of Pittsburgh Medical Center, Pittsburgh
Virginia Cancer Specialists, Fairfax
Sarah Cannon Research Institute, Nashville
START Midwest, Grand Rapids
NEXT Oncology, San Antonio
University of Southern California, Los Angeles
UC San Diego Moores Cancer Center, La Jolla
Stanford Health Care, Stanford
Providence Cancer Institute, Portland
Yale University Cancer Center, New Haven
Massachusetts General Hospital, Boston
Lead Sponsor
Palleon Pharmaceuticals, Inc.
INDUSTRY